SAN DIEGO–(BUSINESS WIRE)—- $GOSS–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2026 financial results on Monday, May 18, 2026. In connection with the earnings release, Gossamer’s management team will host a live conf
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
